Holen Sie sich die Stockscreener-App
262.82
1.11%
2.89
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie's Rinvoq Shows Promise in Vitiligo Trials, ABBV Stock Hig - GuruFocus
AbbVie long-term data buoys Rinvoq for vitiligo - Seeking Alpha
AbbVie Presents Long-Term RINVOQ® Data Showing Continued Repigmentation in Non-Segmental Vitiligo - Investing News Network
Why Is AbbVie (NYSE:ABBV) Suddenly a Must-Watch Healthcare Stocks Stock Today? - kalkinemedia.com
AbbVie to Host Third-Quarter 2026 Earnings Conference Call - Investing News Network
AbbVie to release Q3 2026 earnings on Oct 30 be... - Pluang
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - uk.finance.yahoo.com
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? - Zacks Investment Research
AbbVie stock pre-market at EUR 231.40: minus 0.09 percent - AD HOC NEWS
New report explores the future of aesthetic treatments - kutv.com
AbbVie Stock: Buy, Sell, or Hold in October? - theglobeandmail.com
AbbVie’s eczema drug shows benefit in Phase 2; BioMarin lays off 117 - Endpoints News
AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates - Benzinga
AbbVie unveils promising results for its obesity drug candidate - marketscreener.com
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength - AOL.com
AbbVie (ABBV) Reports Promising Phase 1 Weight Loss Data for ABB - GuruFocus
AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 (ABBV:NYSE) - Seeking Alpha
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 - Investing News Network
AbbVie's Zumilokibart Phase 2 Success Highlights Dividend Sustai - GuruFocus
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress - Investing News Network
At 16 weeks, all three doses of AbbVie’s eczema treatment improved skin more than placebo. - Stock Titan
AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis - Seeking Alpha
Three late-breaking reports will be part of AbbVie's 60 research presentations on skin diseases. - Stock Titan
AbbVie Inc (ABBV) Stock Down 1.1% but Still Overvalued -- GF Sco - GuruFocus
Enterprise value of AbbVie, Inc. – HAN:4AB - TradingView
If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today - Benzinga
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo! Finance Canada
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
Valkai Partners with Abbvie to Apply Advanced Ai Across Targeted Areas of Clinical Development - marketscreener.com
Defensive Dividends: 3 Companies Investors Can Rely On - TradingView
AbbVie (NYSE:ABBV) Wins Juvmo Approval for Parkinson's Disease - kalkinemedia.com
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval - TradingView
AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says - Yahoo Finance
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo - Yahoo Finance
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development - Investing News Network
UnitedHealth, AbbVie And A Health Care Stock On CNBC’s ‘Final Trades’ - Benzinga
Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium - marketscreener.com
AbbVie partners with Valkai to boost AI in clin... - Pluang
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium - Yahoo Finance
Is AbbVie (ABBV) A Bargain After FDA Approval Of JUVMO For Parkinson's? - Yahoo Finance
FDA Approves AbbVie's Juvmo for Parkinson Disease - Drug Topics
Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation? - Yahoo Finance
AbbVie gets FDA approval for Parkinson’s disease drug Juvmo - Investing.com
AbbVie's Tavapadon Wins FDA Nod as First D1/D5 Agonist for Parkinson's - finance.biggo.com
AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says - Benzinga
AbbVie Wins FDA Approval for Parkinson’s Drug JUVMO - grafa.com
AbbVie Won FDA Approval for Parkinson’s Pill Juvmo. Here’s Why Management Already Expects a Slow Start - TIKR.com
AbbVie Receives FDA Approval for Parkinson’s Disease Drug Juvmo - Yahoo Finance
AbbVie (ABBV) Gains FDA Approval for Juvmo, Bolstering Parkinson's Portfolio - GuruFocus
U.S. FDA Approves AbbVie's JUVMO for Parkinson's Disease - Investing News Network
AbbVie Inc. (1ABBV.MI) stock price, news, quote and history - Yahoo Finance Singapore
AbbVie partners with IPO-bound Iambic for AI-led drug discoveries - Crain's Chicago Business
AbbVie Inc Hired Firms, 2019 - OpenSecrets
AI Could Give AbbVie (ABBV) a New Route to Long-Term Pipeline Growth - Yahoo Finance
AbbVie Inc Hired Firms, 2026 - OpenSecrets
AbbVie Inc Lobbyists, 2026 - OpenSecrets
AbbVie Inc Lobbyists, 2025 - OpenSecrets
Comparative Analysis of AbbVie and Johnson & Johnson in a Shifting Market - Intellectia AI
AbbVie Says Botox Exempt From Medicare Price Negotiations - law360.com
US FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie’s drug for Parkinson’s disease - WTAQ
Investment Outlook Comparison: AbbVie vs. Pfizer - Intellectia AI
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? - The Motley Fool
ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO - Reuters
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade - 24/7 Wall St.
Allergan Aesthetics - WCIV
ADARx Pharmaceuticals raises $446 million in upsized IPO - qz.com
0.34%
1.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):